Patent EP0133200A1 successfully refreshed from Google Patents.
EP0133200A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Diagnostic antigen for swine pseudorabies disease virus carriers
Assignee: Iowa State University Research Foundation Inc
•
Filing: 1984-05-18
•
Granted: —
•
Expires: 2004-05-18
Abstract
Abstract A diagnostic antigenic factor for determining swine carriers of pseudorabies is obtained from the culture medium in which the pseudorabies (PR) virus is cultured, the medium being removed at an intermediate time in the PR virus replication cycle. The antigenic factor thus obtained can be used as a complementary antigen with reference to the lectin-bound glycoprotein antigens of PR virus from which immunizing sub-unit vaccines can be prepared. Therefore, sub-unit vaccinated swine which are non-carriers of PR virus can be distinguished from carriers. This result can provide an important tool for control of swine pseudorabies and its eventual eradication.
Inventors
- 👤 Kenneth B. Platt
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 06:45
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/12; A61K39/245; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/569; G01N33/56983; A61K2039/54; A61K2039/541; A61K2039/543; C; C12; C12N; C12N2710/00; C12N2710/00011; C12N2710/16011; C12N2710/16711; C12N2710/16734
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
90 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies disease virus (PR virus), comprising: (a) growing cells adapted for in vitro propagation in which PR virus will replicate; (b) infecting the cell culture with live PR virus; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 2
Independent Claim
90 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies disease virus (PR virus), comprising: (a) growing cells adapted for in vitro propagation in which PR virus will replicate; (b) infecting the cell culture with live PR virus; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 3
Dependent Claim
10 words
The diagnostic factor produced by the method of claim 1.
Claim 4
Dependent Claim
22 words
The method of claim 1 in which said cells are kidney cells, and said culture medium is free of fetal calf serum.
Claim 5
Independent Claim
18 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies virus (PR virus), comprising:
Claim 6
Independent Claim
18 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies virus (PR virus), comprising:
Claim 7
Dependent Claim
94 words
(a) growing cells adapted for in vitro propagation in which PR virus will replicate; (b) infecting the cell culture with live PR virus using from 3 to 12 virus per cell; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle within the time period from 2 to 8 hours after the start of the replication; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 8
Dependent Claim
94 words
(a) growing cells adapted for in vitro propagation in which PR virus will replicate; (b) infecting the cell culture with live PR virus using from 3 to 12 virus per cell; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle within the time period from 2 to 8 hours after the start of the replication; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 9
Dependent Claim
10 words
The antigenic factor produced by the method of claim 4.
Claim 10
Independent Claim
111 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies virus (PF virus), comprising: (a) growing mammalian kidney cells adapted for in vitro propagation to produce a cell culture; (b) infecting the cell culture with live PR virus using about 3 to 12 virus per cell; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle of from about 4 to 6 hours after the start of the replication; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 11
Independent Claim
111 words
The method of preparing a diagnostic antigenic factor for determining swine carriers of pseudorabies virus (PF virus), comprising: (a) growing mammalian kidney cells adapted for in vitro propagation to produce a cell culture; (b) infecting the cell culture with live PR virus using about 3 to 12 virus per cell; (c) replicating the virus in the infected cells in contact with an aqueous culture medium; (d) interrupting the virus replication at an intermediate time in the replication cycle of from about 4 to 6 hours after the start of the replication; and (e) separating the culture medium from the virus- containing cells to obtain an aqueous solution of the diagnostic factor.
Claim 12
Dependent Claim
10 words
The antigenic factor produced by the method of claim 6.
References Cited (Backward Citations)
EP0069407A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.